OncoMatch/Clinical Trials/NCT06717113

A Molecular Probe Targeting BCMA for the Clinical Diagnosis of Multiple Myeloma

Is NCT06717113 recruiting? Yes, currently enrolling (May 2026). This Early Phase 1 trial studies multiple treatments including 18F-FDG and 68Ga-BC1 for multiple myeloma and malignant plasma cell neoplasms.

Treatment: 18F-FDG · 68Ga-BC1 — Multiple Myeloma (MM), the second most common hematological malignancy, continues to pose challenges in precise clinical identification. As a potential solution, nuclear medicine immuno-PET imaging has emerged as a promising approach. However, traditional full-length antibody probes suffer from delayed tumor uptake peaks and low target-to-background ratios, limiting their clinical utility. In our study, a peptide or nanobody targeting BCMA was developed by computer-aided designing, which was subsequently radiolabeled with 68Ga to create a novel molecular probe, 68Ga-MM-BC1. This research aims to overcome the diagnostic limitations of MM and may also offer valuable insights for molecular-targeted imaging in other malignant tumors.